CompletedPHASE1, PHASE2NCT01473264

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

Studying Bronchopulmonary dysplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Clarassance, Inc.
Principal Investigator
Jonathan M Davis, MD, MD
Dept of pediatrics, Winthrop University Hospital, SUNY Stony Brook School of Medicine
Intervention
recombinant human CC10 (rhCC10)(drug)
Enrollment
22 enrolled
Eligibility
All sexes
Timeline
20002003

Study locations (4)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01473264 on ClinicalTrials.gov

Other trials for Bronchopulmonary dysplasia

Additional recruiting or active studies for the same condition.

See all trials for Bronchopulmonary dysplasia

← Back to all trials